Anova Enterprises

Anova Enterprises is a clinical research organization that has developed a collaborative technology platform called AnovaOS. This platform aims to expedite the development and availability of promising new treatments by connecting investigators, researchers, and patients involved in clinical trials. The AnovaOS system allows users to view the status of over 130,000 active studies and facilitates the identification and enrollment of eligible patients for clinical trials.

Anova's platform streamlines the clinical trial process, reducing costs and enabling access to new therapies for a larger patient population. The company partners with pharmaceutical companies and research centers to accelerate the development of innovative drugs and therapies. In September 2023, Anova collaborated with Dizal Pharmaceuticals to expedite the enrollment of patients for clinical trials investigating DZD9008, an irreversible EGFR inhibitor for the treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations.

In March 2023, NeOnc Technologies engaged Anova to pursue a pediatric indication and obtain FDA Fast Track and Rare Pediatric Designation for NEO100, a novel drug delivery method for treating brain and central nervous system diseases. Anova's involvement aimed to support efficient patient identification and enrollment for NEO100 trials in pediatric high-grade gliomas.

Key customers and partnerships

In September 2022, Anova partnered with Mary Crowley Cancer Research, a nonprofit cancer research center, to establish a technology-enabled approach for extending early-phase clinical trials to cancer patients in the Southern and Southwestern US. This collaboration leverages Anova's AnovaOS platform to streamline patient matching and enrollment in targeted therapies, regardless of where the patients receive care.